CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $5.02.

A number of equities analysts have issued reports on CTMX shares. HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, March 7th. Wedbush reissued an “outperform” rating and set a $5.00 target price on shares of CytomX Therapeutics in a research note on Friday, March 7th. Finally, StockNews.com raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, March 10th.

Institutional Trading of CytomX Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC grew its holdings in shares of CytomX Therapeutics by 17.3% during the third quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock valued at $335,000 after buying an additional 41,949 shares during the last quarter. Geode Capital Management LLC lifted its position in CytomX Therapeutics by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock valued at $948,000 after acquiring an additional 34,032 shares in the last quarter. Virtu Financial LLC acquired a new position in CytomX Therapeutics during the 3rd quarter valued at about $104,000. Miller Financial Services LLC bought a new stake in CytomX Therapeutics during the 4th quarter worth approximately $26,000. Finally, Traphagen Investment Advisors LLC purchased a new stake in shares of CytomX Therapeutics in the fourth quarter worth approximately $31,000. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Stock Up 1.9 %

CTMX stock opened at $0.63 on Friday. The firm has a market cap of $50.32 million, a price-to-earnings ratio of 3.70 and a beta of 1.05. The company’s fifty day simple moving average is $0.74 and its 200 day simple moving average is $0.96. CytomX Therapeutics has a 12-month low of $0.56 and a 12-month high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.45. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The company had revenue of $38.09 million for the quarter, compared to the consensus estimate of $13.53 million. Research analysts expect that CytomX Therapeutics will post -0.05 earnings per share for the current year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.